CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 110 enrolled
Drug / intervention
Inflexal Vbiological
Likely dose
Inflexal V 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01631110
NCT01631110Phase 3Completed
CompareCT.gov

Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2012/2013-Season Influenza Vaccine in Elderly and Young Subjects According to EMA Regulations

Crucell Holland BV·interventional·Posted Jun 28, 2012·Updated Dec 20, 2013

In Brief

A Phase 3 clinical trial evaluating Inflexal V for Influenza. Completed, enrolled 110 participants across 1 site.

Detailed Summary

The study is to assess whether the influenza vaccine Inflexal V for season 2012/2013 fulfills the EMA requirements for re-registration of influenza vaccines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesSwitzerland
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 28, 2012
Enrollment StartJul 1, 2012
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.0 years ago

Interventions

Inflexal Vbiological

Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V